Oklo Clears Major Safety Hurdle for Aurora Nuclear Reactor at Idaho Lab
Oklo gets US approval for Aurora reactor safety plan, moving closer to building a small advanced nuclear plant in Idaho.
NOTRELOAD AI
Enliven Therapeutics’ ELVN-001 Delivers Strong Results in Phase 1 CML Study, Aligns with FDA on Phase 3 Design
Early results show performance that is comparable to a widely used Novartis blockbuster and a Merck-owned experimental treatment.
Morgan Stanley: Alcoa’s Sharp Selloff on Alumina Pressure Appears Overdone
Alcoa shares fell on Wednesday after profit warnings on alumina losses driven by energy costs and geopolitical disruptions. Morgan Stanley remains positive.
BTIG Starts Coverage on VOYG with Buy Rating on Defense Growth
BTIG sees Voyager as a Buy with $55 target (~33% upside), boosted by defense deals, acquisitions, and strong bullish trading signals.
Casgevy Outlook: Morgan Stanley’s Take on CRISPR Therapeutics
Morgan Stanley upgraded CRISPR Therapeutics to Equal Weight, $60 target (~21% upside), sees Casgevy growth but mixed valuation views.
Intel Stock Surges as BofA Projects Strong Growth, Sees $6+ EPS by 2030
BofA boosts Intel to Buy, citing AI agent CPU boom and improved manufacturing outlook.